Perceived efficacy of cyclandelate in the treatment of cochleovestibular and retinal disturbances related to cerebrovascular insufficiency. A study in general practice comprising 2772 patients.
To investigate the perceived efficacy and safety of cyclandelate when used in general practice, an open multicentre study was performed comprising 2772 patients with symptoms of vertigo, tinnitus or visual disturbances thought to result from cerebrovascular insufficiency. After 90 days' treatment with cyclandelate 1600 mg daily in 2 doses, both the severity and frequency of these symptoms declined. The general practitioners rated the overall therapeutic efficacy of cyclandelate as 'excellent' or 'good' in 81% of patients, while 77% of patients considered the efficacy of the drug to be 'excellent' or 'good'. Side effects were infrequent and of a mild nature. Thus, when used in the setting of general practice, cyclandelate seems to be a safe and apparently effective treatment for patients with symptoms of vertigo, tinnitus and visual disturbances attributable to chronic cerebrovascular insufficiency.
D000328:Adult; D000368:Aged; D002561:Cerebrovascular Disorders / Q000150:complications*; D003051:Cochlea; D003495:Cyclandelate / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007759:Labyrinth Diseases / Q000188:drug therapy / Q000209:etiology; D008297:Male; D008333:Mandelic Acids / Q000627:therapeutic use*; D008875:Middle Aged; D012164:Retinal Diseases / Q000188:drug therapy* / Q000209:etiology; D014722:Vestibule, Labyrinth
D008333:Mandelic Acids; D003495:Cyclandelate